© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
March 31st 2021
Jessica K. Altman, MD, and Naval G. Daver, MD, share their approaches to genetic testing for FLT3 and other actionable mutations in acute myeloid leukemia (AML).
Insight regarding the assessment of the prevalence of FLT3-ITD versus FLT3-TKD mutations and allelic burden in newly diagnosed acute myeloid leukemia.
April 7th 2021
Leukemia experts discuss the role of genetic testing to check for FLT3 mutations at the time of relapse in acute myeloid leukemia.
Jessica K. Altman, MD, reviews the safety and efficacy of gilteritinib as seen in the ADMIRAL trial for the treatment of relapsed/refractory acute myeloid leukemia.
April 14th 2021
Experts in leukemia comment on the utilization of FLT3 inhibitors in combination with chemotherapy in early and recurrent acute myeloid leukemia.
Naval G. Daver, MD, reviews the safety and efficacy of quizartinib in relapsed/refractory acute myeloid leukemia as seen in the phase 3 QuANTUM-R study.
April 21st 2021
Examining the need to achieve a true CR (complete remission), especially with recent targeted therapies in relapsed/refractory acute myeloid leukemia.
Naval G. Daver, MD, leads the discussion on the use sorafenib in combination with hypomethylating agents (HMA) for the treatment of relapsed FLT3-mutated AML.
April 28th 2021
Jessica K. Altman, MD, and Naval G. Daver, MD, discuss what is known in terms of mechanisms of resistance to FLT3 inhibitors used to treat acute myeloid leukemia.
Experts in hematology comment on when it’s appropriate to use gilteritinib, particularly as a combination therapy, to treat patients with FLT3-mutated acute myeloid leukemia.